Biogen (BIIB) Cost of Revenue (2009 - 2026)

Biogen's Cost of Revenue history runs 18 years deep, the most recent figure standing at $661.0 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 5.04% year-over-year to $661.0 million; the TTM figure through Mar 2026 stood at $2.4 billion (up 1.6% YoY), while the FY2025 annual figure was $2.4 billion, up 4.06% from the prior year.
• Cost of Revenue was $661.0 million for Q1 2026 at Biogen, up from $495.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $674.4 million in Q3 2025 to a low of $164.0 million in Q4 2022.
• Historically, Cost of Revenue has averaged $520.4 million across 5 years, with a median of $583.5 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue plunged 42.48% in 2022, then surged 255.79% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $164.0 million in 2022, then changed by 0.0% to $164.0 million in 2023, then soared by 255.79% to $583.5 million in 2024, then slipped by 15.08% to $495.5 million in 2025, then soared by 33.4% to $661.0 million in 2026.
• The last three Cost of Revenue figures came in at $661.0 million (Q1 2026), $495.5 million (Q4 2025), and $674.4 million (Q3 2025), per Business Quant data.